Ratio Therapeutics raised $70 million for radiopharmaceutical trials as it advances its pipeline through clinical development. The Boston-based company said the Series C came from existing investors including Duquesne Family Office and Bristol Myers Squibb, alongside new backers. Management framed the financing as support for continued radiopharma trial work and program execution, with the company positioning its platform to move rapidly from trials into broader evaluation of radioligand candidates. The round adds to a steady flow of capital into radiopharmaceutical development as sponsors compete on imaging and targeted therapeutic modalities. For investors, the combination of experienced institutional participation and clear clinical trial intent reinforces that radiopharma remains a priority area for late-stage translational investment.